View Risk


Article data
Guan (2020)
Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis
https://doi.org/10.1183/13993003.00547-2020
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7098485/

Results
Comorbidities
Cancer (Present vs. Not present)
COVID-19 (severe/critical)
Hazard ratio: 3.500 (1.600-7.640) Adjusted model

Study characteristics

China

Retrospective case study

Medical records

1590

1590 cases from 575 hospitals in 31 province/autonomous regions/provincial municipalities

Of these 1590 cases, the mean age was 48.9 years. 686 patients (42.7%) were females. 647 (40.7%) patients were managed inside Hubei province, and 1334 (83.9%) patients had a contact history of Wuhan city. The most common symptom was fever on or after hospitalisation (88.0%), followed by dry cough (70.2%). Fatigue (42.8%) and productive cough (36.0%) were less common. At least one abnormal chest CT manifestation (including ground-glass opacities, pulmonary infiltrates and interstitial disorders) was identified in more than 70% of patients. Severe cases accounted for 16.0% of the study population. 131 (8.2%) patients reached to the composite endpoints during the study.

Median

10 Day


Results

COVID-19 (severe/critical)

131

Patients who reached composite endpoints, which consisted of admission to intensive care unit, or invasive ventilation or death.

Comorbidities

Cancer

Comorbidities were determined based on patient's self-report on admission.

Not present

1460

Present

130

Hazard ratio

3.500 (1.600-7.640)

No

Yes

Yes

The age and smoking status were adjusted for in the proportional hazards regression model because they have been recognised as the risk factors of comorbidities even in the general population.


Other information

After adjusting for age and smoking status, COPD [hazards ratio (HR) 2.681, 95% confidence interval (95%CI) 1.424??5.048], diabetes (HR 1.59, 95%CI 1.03??2.45), hypertension (HR 1.58, 95%CI 1.07??2.32) and malignancy (HR 3.50, 95%CI 1.60??7.64) were risk factors of reaching to the composite endpoints. The HR was 1.79 (95%CI 1.16??2.77) among patients with at least one comorbidity and 2.59 (95%CI 1.61??4.17) among patients with two or more comorbidities.

Average

No

Go Back